Cargando…
Development of molecular and pharmacological switches for chimeric antigen receptor T cells
The use of chimeric antigen receptor (CAR) T cell technology as a therapeutic strategy for the treatment blood-born human cancers has delivered outstanding clinical efficacy. However, this treatment modality can also be associated with serious adverse events in the form of cytokine release syndrome....
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6833279/ https://www.ncbi.nlm.nih.gov/pubmed/31709128 http://dx.doi.org/10.1186/s40164-019-0151-z |